Skip to main content Skip to search Skip to main navigation

PIC/S: Guidance on Remote Assessments

PIC/S has published two guidance documents for inspectors: "Guidance on Remote Assessments" (PI 056-1) and "Aide Memoire on Remote Assessments" (PI 057-1). These documents will enter into force on 1 January 2025.

The PIC/S states that the remote assessment and hybrid inspection will have a place in an inspector‘s toolkit beyond the pandemic.

They soon will be available in our GMP knowledge portal, the GMP Compliance Adviser.

Guidance on remote assessments
The guidance distinguishes between fully interactive remote assessments, partially interactive remote assessments, desktop assessments, and hybrid inspections.
It covers the logistics and the technical requirements for remote inspections.

A feasibility check for a remote inspection using a risk assessment is mandatory. Factors to be considered include:

  • Previous inspection history
  • Activities carried out at site
  • Length of time since last on-site inspection
  • Information relating to the site from any regulatory authority / source
  • Changes since last inspection
  • Internet connectivity of site and of inspectors

Documentation requirements are also given. For example, the GMP certificate should clearly state whether the assessment/inspection was performed remotely, on-site or hybrid.

Aide Memoire on remote inspections
The Aide Memoire provides best practices and summaries for preparing and conducting remote assessments and post-inspection activities. It also provides prompts and questions to guide users through these processes.
Issues raised include, for example:

  • Pre-inspection teleconference with the site
  • Secure platform for sharing documents
  • Connectivity test
  • Need for an independent translator
  • Daily tentative schedule to ensure the availability of subject matter exterts (SMEs)
  • Site tours?
  • What type of document will be issued after the remote assessment

Source:

PIC/S: News

Meet the GMP Compliance Adviser

The GMP Compliance Adviser is the world's largest knowledge portal for quality management in the pharma business. 

The demo access is non-binding and ends automatically.

Test it now for free

You may also be interested in the following articles:

EMA: Revision of Annex 6 - Manufacture of Medicinal Gases

EMA: Revision of Annex 6 - Manufacture of Medicinal Gases

EMA and PIC/S have published a concept paper announcing a targeted revision of Annex 6 Manufacture of Medicinal Gases of the EU GMP Guide. The last update dates from 2010. The revision aims to reflect current manufacturing practice, technological progress and lessons learned from the COVID-19 pandemic.

Read more
EMA: Concept Paper on the Revision of Annex 15

EMA: Concept Paper on the Revision of Annex 15

EMA and PIC/S have published a concept paper outlining a targeted revision of Annex 15 (Qualification and Validation).

Read more
Human Resource Management as a Key to Success

Human Resource Management as a Key to Success

The pharmaceutical industry in Germany and other countries, too, faces considerable challenges in the area of human resource management. These problems have far-reaching implications for the competitiveness and innovative power of the industry.

Read more
What do Typical Manufacturing Processes for Sterile Products look like?

What do Typical Manufacturing Processes for Sterile Products look like?

Here's the answer:
Read more
EMA: Reflection Paper on the Qualification of Non-Mutagenic Impurities (NMIs)

EMA: Reflection Paper on the Qualification of Non-Mutagenic Impurities (NMIs)

The EMA has published a new reflection paper outlining its current thinking on the qualification of non-mutagenic impurities (NMIs). The paper addresses recommended approaches for evaluating the safety of new or increased impurity levels, particularly when such impurities exceed the ICH Q3A/Q3B qualification thresholds and are identified after completion of non-clinical toxicology studies.

Read more
EMA: Discussions on the Revised ERA Guideline

EMA: Discussions on the Revised ERA Guideline

During the second industry stakeholder webinar on the revised guideline on environmental risk assessment (ERA) for medicinal products for human use, the European Medicines Agency (EMA) addressed key implementation challenges observed during the first year of application.
Read more
Previous
Next